Chronic intermittent hypobaric hypoxia attenuates skeletal muscle ischemia-reperfusion injury in mice

Cheng, Wenjie; Liu, Xin; Zhang, Li; Guo, Xinqi; Wang, Fuwei; Zhang, Yi; Tian, Yanming

doi:10.1016/j.lfs.2019.06.008

Cited by 15 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has long been known that early ischemic preconditioning of organs that were ischemia-reperfusion would reduce the damage to organs, which seemed to be related to the hypoxic protection mechanism of the body. In a trial conducted by Cheng et al early intermittent chronic hypoxic preconditioning of skeletal muscle in rats with ischemia-reperfusion resulted in decreased signs of inflammation such as tumor necrosis factor and macrophage ( 76 ), and the hypoxic protective mechanism appeared to have Inhibition of inflammation reduces the effects of ischemia-reperfusion injury ( 77 ).…”

Section: Roxadustat: a New Option For Treating Inflammatory Anemia Inmentioning

confidence: 99%

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat

Yan

2020

Front. Med.

View full text Add to dashboard Cite

Anemia is a complication of chronic kidney disease (CKD), primarily due to insufficient secretion of erythropoietin (EPO) by the kidney. Erythropoiesis-stimulating agents (ESAs) are used to treat anemia associated with chronic kidney disease. A poor response to ESAs has been associated with inflammation. Inflammation can affect erythrocytes and its production in many ways, but mainly through the inflammatory cytokine IL-6 to stimulate the synthesis of hepcidin in the liver. Hepcidin causes iron insufficiency, which causes erythrocytes to fail to mature normally. In addition, inhibition of bone marrow erythroid precursor cells by inflammatory cytokines such as IL-1 and TNF-α also affects bone marrow hematopoiesis. These cytokines are also important factors leading to EPO resistance. Roxadustat is a new drug for the treatment of renal anemia. In addition to promoting the production of EPO, clinical trials have shown that it can significantly reduce hepcidin and can potentially be used for the treatment of inflammation-induced anemia in CKD.

show abstract

Section: Roxadustat: a New Option For Treating Inflammatory Anemia Inmentioning

confidence: 99%

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat

Yan

2020

Front. Med.

View full text Add to dashboard Cite

show abstract

“… 32 , 33 Recently, IH was shown to induce impairment of muscle tissue, leading to various changes in the secretion of inflammatory cytokines called myokines. 34 Myokines, which are bioactive mediators produced and released by myocytes, play important roles in many physiological and pathophysiological processes that contribute in the modulation of homeostasis, lipid and/or glucose metabolism, and inflammation. 18 , 35 , 36 IL‐8, also referred to as chemokine (C‐X‐C motif) ligand 8, is a key regulator of monocyte infiltration into skeletal muscle and is involved in muscle tissue inflammation and insulin resistance.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of IL‐8, osteonectin, and myonectin mRNAs by intermittent hypoxia via OCT1‐ and NRF2‐mediated mechanisms in skeletal muscle cells

Takasawa

Shobatake

Itaya‐Hironaka

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Sleep apnoea syndrome is characterized by recurrent episodes of oxygen desaturation and reoxygenation (intermittent hypoxia [IH]) and is a risk factor for insulin resistance/Type 2 diabetes. The induction of insulin resistance in skeletal muscle is a key phenomenon to develop diabetes. However, the mechanisms linking IH stress and insulin resistance remain elusive. We exposed human RD and mouse C2C12 muscle cells to normoxia or IH and measured their mRNA levels by real‐time RT‐PCR. We found that IH significantly increased the mRNA and protein levels of muscle‐derived insulin resistance‐factors (myokines) such as IL‐8, osteonectin (ON), and myonectin (MN) in muscle cells. We further analysed the IH‐induced expression mechanisms of IL‐8, ON, and MN genes in muscle cells. Deletion analyses of the human myokine promoter(s) revealed that the regions −152 to −151 in IL‐8, −105 to −99 in ON, and − 3741 to −3738 in MN promoters were responsible for the activation by IH in RD cells. The promoters contain consensus transcription factor binding sequences for OCT1 in IL‐8 and MN promoters, and for NRF2 in ON promoter, respectively. The introduction of siRNA for OCT1 abolished the IH‐induced expression(s) of IL‐8 and MN and siRNA for NRF2 abolished the IH‐induced expression of ON.

show abstract

“…Previous studies showed that HIF had antiinflammatory effects and promoted the resolution of inflammation (Kiers et al, 2016). Cheng et al (2019) found that early intermittent hypoxia preconditioning of rat skeletal muscle inhibited inflammation and had a protective effect on acute IRI of skeletal muscle. In addition, upregulation of HIF-2α can reduce inflammasome hyperactivation and prevent cell death (Li et al, 2021d).…”

Section: Effect Of Roxadustat On Inflammationmentioning

confidence: 99%

Roxadustat: Not just for anemia

Zhu

Jiang²,

Wei³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent studies found it also has potential for the treatment of other hypoxia-related diseases. Although clinical studies have not yet found significant adverse or off-target effects of roxadustat, clinicians must be vigilant about these possible effects. Hypoxia-inducible factor regulates the expression of many genes and physiological processes in response to a decreased level of oxygen, but its role in the pathogenesis of different diseases is complex and controversial. In addition to increasing the expression of hypoxia-inducible factor, roxadustat also has some effects that may be HIF-independent, indicating some potential off-target effects. This article reviews the pharmacological characteristics of roxadustat, its current status in the treatment of renal anemia, and its possible effects on other pathological mechanisms.

show abstract

Chronic intermittent hypobaric hypoxia attenuates skeletal muscle ischemia-reperfusion injury in mice

Cited by 15 publications

References 37 publications

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat

Upregulation of IL‐8, osteonectin, and myonectin mRNAs by intermittent hypoxia via OCT1‐ and NRF2‐mediated mechanisms in skeletal muscle cells

Roxadustat: Not just for anemia

Contact Info

Product

Resources

About